Anti-F. tularensis LVS Bacterioferritin (bfr) [163] Antibody

This mouse IgG2a monoclonal antibody [163] was generated against sublethal infection with F. tularensis LVS and is specific for F. tularensis LVS protein bacterioferritin (BFN).


  • Reacts with F. tularensis LVS protein bacterioferritin (BFN)
  • Does not react with ortholog from F. tularensis SchuS4 or F. novicida
  • Suitable for Western Blot, Immunoprecipitation, ELISA and Immunofluorescence applications

Francisella tularensis is a small pathogenic gram-negative, nonmotile, aerobic bacteria and the causative agent of tularemia. Also known as "rabbit fever" the highly contagious bacteria can be spread from animals to humans, through a vector such as fleas or mosquitoes. F. tularensis has been considered to be encapsulated for over 40 years based on the rough colony phenotype and presence of polysachharides structures on the organism. Francisella tularensis is classified as a Category A biological agent and symptoms include fever, headache and body aches.

From the laboratory of Anne G. Savitt, PhD, Stony Brook University

The Investigator's Annexe Part of The Investigator's Annexe program.

Catalog Number Product DataSheet Size AVAILABILITY Price Qty
Anti-F. tularensis LVS Bacterioferritin (bfr) [163] Antibody
100ug In stock
Regular Price:$375.00
On Sale:

Product Type: Antibody
Antigen: Bacterioferritin (Bfn)
Accession ID: Q5ISD2, YP_513376.1
Molecular Weight: 16 kDa
Isotype: IgG2a
Clonality: Monoclonal
Clone Name: 163
Reactivity: Francisella tularensisLVS
Immunogen: Sublethal infection with F. tularensisLVS
Species Immunized: Mouse
Purification Method: FPLC on Protein G Sepharose
Method Used to Determine Concentration: OD280 (Nanodrop)
Buffer: PBS
Tested Applications: WB, IP, ELISA, IF. Use at 1-10 ug/mL
Concentration: 2.5 mg/mL
Storage: -20C
Shipped: Cold packs

From the laboratory of Anne G. Savitt, PhD, Stony Brook University
  1. Savitt AG, Mena-Taboada P, Monsalve G, Benach JL. Francisella tularensis infection-derived monoclonal antibodies provide detection, protection, and therapy. Clin Vaccine Immunol. 2009 Mar;16(3):414-22.

If you publish research with this product, please let us know so we can cite your paper.